Current Status
Not Enrolled
Price
Free
Get Started

Program Director

Khalid Al Rasadi, MD

Program Director

Raul D Santos, MD, MSc, PhD

2020 Middle East Summit on Residual Cardiovascular Risk

Cardiovascular diseases remain the #1 cause of death and disability globally and are on the rise in developing regions of the world. Despite advances in the control of the classic risk factors like lowering LDL-Cholesterol and efforts to manage contributing disease factors such as diabetes, obesity and hypertension, patient risk for developing ASCVD can still remain high. This course was designed to educate on the complete examination and clinical approaches to the treatment of residual risk (RR) factors that may persist and ultimately continue to drive the patient’s potential for cardiovascular events.

The IAS is pleased to present thirteen (13) recordings from the live accredited sessions presented at the 2020 Middle East Residual Risk Cardiovascular Summit held in Dubai on February 21-22, 2020. This comprehensive educational event was designed for medical professionals in the clinical setting.

The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the speakers and participants for sharing their experience and for helping IAS to develop this global faculty of experts featured in the presentations.

Pre-activity information

This 2020 Middle East Summit on Residual Cardiovascular Risk is a comprehensive educational campaign targeted to meet the educational needs of medical professionals in clinical practice engaged in the prevention or the management of patients demonstrating risk or with established cardiovascular disease. 

 

By participating in these educational offerings, the learner is expected to be able to:

  

1) Identify opportunities to address ASCVD residual risk factors, including under-treatment of related conditions and non-LDL related risk conditions

2) Describe the association of LDL-C driven RR with ASCVD RR, including the role of intensive LDL lowering on risk reduction 

3) Select evidence-based residual risk reduction interventions, including modifying TGL

4) Distinguish glucose-lowering agents associated with independent ASCVD risk reduction effects, including GLP-1 receptor agonists and SGLT2 inhibitors

5) List the pros and cons of more intensive blood pressure lowering with regards to RR

6) Describe the epidemiology and association of CKD especially in diabetic and or hypertensive individuals with cardiovascular disease 

7) Recall the association of Lp(a) with ASCVD Risk, epidemiology, genetics and identify upcoming clinical trials exploring the use of specific Lp(a) inhibitors.

8) Identify biomarkers associated with inflammation-driven ASCVD RR, including CRP and design inflammation management plans to reduce RR, including exercise and weight loss

9) Describe the association of increased thrombotic RR with ASCVD, including the role of dual antiplatelet therapy, single antiplatelet or dual antiplatelet therapy plus low-dose NOAC in reducing RR 

 
 

The IAS is proud to present this esteemed global faculty.  More information on each faculty member can be found here.

 

Khalid Al-Rasadi, MD

Disclosures

Date of Disclosures

Consultant or advisory board member from Astra Zeneca, Pfizer, Sanofi, Aegerion and Abbott. Grant and Research support received from Sanofi.

22-02-2020

Raul D Santos, MD, MSc, PhD

Disclosures

Date of Disclosures

Honorarium for research activities from Amgen, Kowa, Esperion, Sanofi/Regeneron. Honorarium for speaker activities from Amgen, Ache, Astra Zeneca, Merck, MSD, Pfizer, PTC and Novo Nordisk.

22-02-2020

Tarek M Fiad, MBBCh, FRCPI, FRCP, MD

There are no Disclosure Statements against this Module for Tarek M Fiad, MBBCh, FRCPI, FRCP, MD

 

Dr. Hani Sabbour, MD, FACC, FHRS, FASE

Disclosures

Date of Disclosures

Speakers Bureau: AZ, Abbott, Merck,Amgen, Aegerion,Sanofi

22-02-2020

Dr. Rabih R. Azar, MD, MPH, FACC

Disclosures

Date of Disclosures

Commercial: Astra-Zeneca; Sanofi; Boehringer; Pfizer; Roche; MSD; Servier; Abbot; Boston Scientific.

22-02-2020

Omar M. Hamoui, MD

Disclosures

Date of Disclosures

Educational Activities: Honoraria for Educational Activities, over 10 companies

22-02-2020

Dr. Abdullah Shehab

There are no Disclosure Statements against this Module for Dr. Abdullah Shehab

Dr. Khalid Al Habib

There are no Disclosure Statements against this Module for Dr. Khalid Al Habib

Staff Disclosures

Staff involved with the development of this activity have nothing to disclose.

Moderator disclosures

Dr Fahad Al Nouri

Disclosures

Date of Disclosures

Advisory Board for: Amgen, Amryt; Lecturing for Amgen; Research grant from Amgen

22-02-2020

Dr. Niaz Khan

There are no Disclosure Statements against this Module for Dr. Niaz Khan

Dr Wael Al Mahmeed

There are no Disclosure Statements against this Module for Dr. Wael Al Mahmeed

Dr Malek Mohamed

There are no Disclosure Statements against this Module for Dr. Malek Mohamed

Dr Abdul Majeed Brek Al Zubaidi

There are no Disclosure Statements against this Module for Dr. Malek Mohamed

The IAS is very grateful to Biologix FzCo for supporting the 2020 Middle East Residual Risk Cardiovascular Summit through an unrestricted educational grant. We also thank all the faculty and clinician attendees from throughout the Middle East who shared their experience and contributed to the IAS in its global mission.

When viewing each activity look for “Materials” tab to download PDF Slides

Click on an activity listed below to begin.

Cost Effective Patient Management to Reduce Mortality Copy

See more...

How the New Guidelines are Approaching the Residual Risk Copy

See more...

Chronic Kidney Disease, Vascular Disease and Residual Risk Copy

See more...

Triglyceride-Rich Lipoprotein Residual Risk Copy

See more...

An Overview: Addressing Residual Risk in 2020 Copy

See more...

CVD Burden of Illness in the Gulf Region and Unmet Medical Needs

See more...

Cost Effective Patient Management to Reduce Mortality

See more...

How the New Guidelines are Approaching the Residual Risk

See more...

Chronic Kidney Disease, Vascular Disease and Residual Risk

See more...

« » page 1 / 2